Abstract
There is considerable variation in reimbursement policies in Asian countries and this is likely to have an impact on treatment practice for chronic hepatitis B (CHB). Consequently a survey of leading hepatologists was performed to evaluate such policies and their impact on management of CHB in the Asia Pacific region. A questionnaire was sent to key hepatologists in Asia Pacific for information on CHB reimbursement policy-its nature, coverage, funding source, duration, review strategy and impact on Asia Pacific Association for the Study of the Liver (APASL) CHB guidelines. The results were analysed and described. Leading hepatologists from 16 Asia Pacific countries responded. Almost all of the countries have reimbursement policies but eligibility varied from only a limited group (e.g. civil servants only) to universal access. In most instances reimbursement was from the central government (except China, Pakistan and Hong Kong). Reimbursement policies were usually created by Ministry of Health committees, who received input from medical professionals, although they may not be aware of the APASL guidelines. Policies were limited by available resources, funds and prioritization. Where there was a regular review this occurred betwe...Continue Reading
References
Aug 10, 2000·Medical Decision Making : an International Journal of the Society for Medical Decision Making·R A HirthW G Weissert
Dec 18, 2001·Health Economics·P P Sendi, A H Briggs
Oct 8, 2004·The New England Journal of Medicine·Yun-Fan LiawUNKNOWN Cirrhosis Asian Lamivudine Multicentre Study Group
Nov 12, 2005·BMJ : British Medical Journal·David B EvansUNKNOWN WHO Choosing Interventions that are Cost Effective (CHOICE) Millennium Development Goals Team
Feb 8, 2006·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·D Lavanchy
Feb 3, 2007·Pharmacy World & Science : PWS·Michelle A King, Michael S Roberts
Aug 12, 2009·Hepatology International·Siwaporn ChainuvatiXin Xin Zhang
Aug 12, 2009·Hepatology International·Yock Young DanSeng Gee Lim
Sep 5, 2009·Vaccine·Xiaofeng LiangYu Wang
Jun 26, 2012·Clinics in Laboratory Medicine·Priya Abraham
Aug 16, 2012·Clinical and Molecular Hepatology·UNKNOWN Korean Association for the Study of the Liver
Dec 13, 2012·Antiviral Therapy·Seng Gee LimKeat Hong Lee
Dec 19, 2012·Lancet·Rafael LozanoZiad A Memish
Apr 24, 2013·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Eiji Tanaka, Akihiro Matsumoto
Oct 5, 2013·Clinical and Experimental Nephrology·Hirofumi Makino, Ken-Ei Sada
Nov 10, 2013·PloS One·Pieter Van HerckDirk Ramaekers
Dec 18, 2013·Antiviral Therapy·Victoria AramaUNKNOWN AI463-121 European Longitudinal Chronic Hepatitis B Study Group
Jun 1, 2012·Hepatology International·Yun-Fan LiawMasao Omata
Jun 1, 2013·Hepatology International·Keat Hong LeeSeng Gee Lim
Citations
Nov 26, 2015·Gastroenterology Clinics of North America·Yock Young Dan, Seng Gee Lim
Mar 29, 2016·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Yao-Chun HsuJaw-Town Lin
Dec 10, 2016·BMJ Open Gastroenterology·Yoona A KimMindie H Nguyen
Jan 26, 2017·Journal of Gastroenterology and Hepatology·Yao-Chun HsuJaw-Town Lin
Jan 16, 2018·Alimentary Pharmacology & Therapeutics·W-K ChanV W-S Wong
Jul 15, 2015·The Korean Journal of Internal Medicine·Seng Gee Lim, Yock Young Dan
May 26, 2018·Alimentary Pharmacology & Therapeutics·V L ChenM H Nguyen
Apr 19, 2020·Hepatology International·Rong Fan, Jinlin Hou
Jan 10, 2020·Journal of Clinical and Translational Hepatology·Shan ShanUNKNOWN CR-HepB study group, Beijing, China
Jul 14, 2020·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Ameer AbutalebAbhijit Chowdhury
Jan 26, 2021·Clinical Liver Disease·Prowpanga UdompapRino Gani